ViiV Healthcare unveiled 24-week data on Friday from the Phase IIIb/IV STRIIVING study, an open-label study to determine the efficacy, safety and tolerability of changing from an antiretroviral therapy (ART) to the once-daily, fixed-dose dolutegravir-based regimen, Triumeq in virologically suppressed adults diagnosed with HIV-1.
Study subjects were adults who remained on their existing ART to 24 weeks. STRIIVING achieved its primary endpoint, indicating that viral suppression was non-inferior for patients switching to abacavir/dolutegravir/lamivudine (Triumeq) to treat their disease.
No patients in the study experienced protocol-defined virologic failure; therefore no patients were evaluated for treatment-emergent resistance.
"For clinicians, choosing among antiretroviral therapies now involves balancing efficacy with factors such as tolerability, dosing, ability to use with other medications and resistance profile," ViiV Healthcare Chief Scientific and Medical Officer John Pottage said. "These data support the use of once-daily abacavir/dolutegravir/lamivudine as a treatment option in the switch setting for appropriate patients.”
Commonly reported adverse reactions to Triumeq included insomnia, headache and fatigue.
For more information on ViiV Healthcare or its products, visit www.viivhealthcare.com.
ViiV Healthcare is a global specialist HIV company established in 2009 by GlaxoSmithKline and Pfizer. Shionogi joined in 2012.
